Table 1 Epidemiological, clinical, and virologic characteristics of the study sample
From: Italian observational study on HPV infection, E6, and p16 expression in men with penile cancer
Mean age (SD), years | 68.0 (11.6) |
Age ≥ 55 years, n (%) | 28/32 (87.5) |
Civil status, n (%) | |
Married | 13/17 (76.5) |
Single | 2/17 (11.8) |
Widower | 2/17 (11.8) |
Occupational status, n (%) | |
Employed | 7 (38.9) |
Retired | 11 (61.1) |
Familiarity for carcinoma, n (%) | 1/15 (6.7) |
Suspected diagnosis of carcinoma, n (%) | 23/24 (92.0) |
Cancer diagnosed before 2010, n (%) | 10.32 (31.3) |
Anatomic site, n (%) | |
Glans | 24/32 (75.0) |
Penis | 8/32 (25.0) |
Histopathological results, n (%) | |
Squamous Cell Carcinoma | 30/32 (93.8) |
Hyperplasia | 1/32 (3.1) |
Fibrosis | 1/32 (3.1) |
Well differentiated, n (%) | 19/32 (59.4) |
Moderately differentiated, n (%) | 8/32 (25.0) |
Poorly differentiated, n (%) | 5/32 (15.6) |
Histopathological grading (AJCC), n (%) | |
G1 | 19/32 (59.4) |
G2 | 8/32 (25.0) |
G3 | 5/32 (15.6) |
Primary tumor (T) (AJCC), n (%) | |
Tis | 3/32 (9.4) |
T1 | 18/32 (56.3) |
T1a | 2/32 (6.3) |
T1b | 1/32 (3.1) |
T2 | 1/32 (3.1) |
T3 | 4/32 (12.5) |
NC | 3/32 (9.4) |
HPV positivity, n (%) | 9/32 (28.1) |
HPV-16 | 7/32 (21.9) |
HPV-56 | 2/32 (6.3) |
HPV-35 | 1/32 (3.1) |
p-16 immunohistochemistry positivity, n (%) | 7/32 (21.9) |
E6 gene positivity, n (%) | 5/7 (71.4) |
Outcome, died | 14/32 (43.8) |